*** p ≤ 0 001, ** p ≤ 0 01, * p ≤ 0 05 (one-way ANOVA) (JPEG 126

*** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05 (one-way ANOVA). (JPEG 126 KB) References 1. Baker DM, Jones JA, Nguyen-Van-Tam JS, Lloyd JH, Morris DL, Bourke JB, Steele RJ, Hardcastle JD: Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. Br J Surg 1994, 81:1054–1056.PubMedCrossRef 2. Simon A, Ammann RA, Wiszniewsky G, Bode U, Fleischhack G, Akt inhibitor Besuden MM: Taurolidine-citrate

lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infect Dis 2008, 8:102.PubMedCrossRef 3. Koldehoff M, Zakrzewski JL: Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 2004, 24:491–495.PubMedCrossRef 4. Jacobi CA, Menenakos C, Braumann C: Taurolidine–a new drug with anti-tumor buy LY3023414 and anti-angiogenic

effects. Anticancer Drugs 2005, 16:917–921.PubMedCrossRef 5. Braumann C, Schoenbeck M, Menenakos C, Kilian M, Jacobi CA: Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats. Clin Exp Metastasis 2005, 22:77–83.PubMedCrossRef 6. Chromik AM, Daigeler A, Hilgert C, Bulut D, Geisler A, Liu V, Otte JM, Uhl W, Mittelkotter U: Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. J Invest Surg 2007, 20:339–348.PubMedCrossRef 7. Daigeler A, Chromik AM, Geisler A, Bulut D, Hilgert C, Krieg A, Klein-Hitpass L, Lehnhardt M, Uhl W, Mittelkötter U: Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma MG-132 manufacturer cells of the esophagus. Int J Oncol 2008, 32:1205–1220.PubMedCrossRef OSI-027 cost 8. Stendel R, Stoltenburg-Didinger G, Al Keikh CL, Wattrodt M, Brock M: The effect of taurolidine on brain tumor cells. Anticancer Res

2002, 22:809–814.PubMed 9. Stendel R, Biefer HR, Dekany GM, Kubota H, Munz C, Wang S, Mohler H, Yonekawa Y, Frei K: The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. Autophagy 2009, 5:194–210.PubMedCrossRef 10. Braumann C, Jacobi CA, Rogalla S, Menenakos C, Fuehrer K, Trefzer U, Hofmann M: The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma–a mouse model. J Surg Res 2007, 143:372–378.PubMedCrossRef 11. Sun BS, Wang JH, Liu LL, Gong SL, Redmond HP: Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. J Surg Oncol 2007, 96:241–248.PubMedCrossRef 12. Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W, Hopkins-Donaldson S: Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. Lung Cancer 2007, 56:327–336.PubMedCrossRef 13. Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, Mutti L, Gaudino G: Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma.

Comments are closed.